1. An antibody or antigen binding fragment which binds to TIM-3, optionally isolated, comprising a heavy chain variable region sequence having the sequence of SEQ ID NO:22 and a light chain variable region sequence having the sequence of SEQ ID NO:2.

2. The antibody, or antigen binding fragment, of claim 1, wherein the antibody is cytotoxic to TIM-3 expressing cells.

3. The antibody, or antigen binding fragment, of claim 1 or claim 2, wherein the antibody or antigen binding fragment is effective to restore T-cell function in T-cells exhibiting T-cell exhaustion or T-cell anergy.

4. An antibody or antigen binding fragment, optionally isolated, which binds to TIM-3, which is a bispecific antibody or a bispecific antigen binding fragment comprising (i) an antigen binding fragment according to any of one of claims 1 to 3, and (ii) an antigen binding domain which binds to a target protein other than TIM-3.

5. The antibody, or antigen binding fragment, of claim 4, wherein the antigen binding domain which binds to a target protein other than TIM-3 binds to CD3 or a CD3 polypeptide.

6. An *in vitro* complex, optionally isolated, comprising an antibody, or antigen binding fragment, according to any one of claims 1 to 5 bound to TIM-3.

7. A composition comprising the antibody, or antigen binding fragment, of any one of claims 1 to 5 and at least one pharmaceutically-acceptable carrier.

8. An isolated nucleic acid encoding the antibody, or antigen binding fragment, of any of one of claims 1 to 5.

9. A vector comprising the nucleic acid of claim 8.

10. A host cell comprising the vector of claim 9.

11. A method for making an antibody, or antigen binding fragment, of any of one of claims 1 to 5 comprising culturing the host cell of claim 10 under conditions suitable for the expression of a vector encoding the antibody, or antigen binding fragment, and recovering the antibody, or antigen binding fragment.

12. An antibody or antigen binding fragment according to any of one of claims 1 to 5 for use in therapy, or in a method of medical treatment.

13. An antibody or antigen binding fragment according to any of one of claims 1 to 5 for use in the treatment of cancer, a T-cell dysfunctional disorder, or an infectious disease.

14. Use of an antibody or antigen binding fragment according to any of one of claims 1 to 5 in the manufacture of a medicament for use in the treatment of cancer, a T-cell dysfunctional disorder, or an infectious disease.

15. A method, *in vitro*, of killing a cell that expresses TIM-3 comprising administering an antibody or antigen binding fragment according to any one of claims 1 to 5 to a cell that expresses TIM-3.

16. A method, *in vitro*, of enhancing T-cell function comprising administering an antibody or antigen binding fragment according to any one of claims 1 to 5 to a dysfunctional T-cell.

17. A method comprising contacting a sample containing, or suspected to contain, TIM-3 with an antibody or antigen binding fragment according to any one of claims 1 to 5 and detecting the formation of a complex of antibody, or antigen binding fragment, and TIM-3.

18. A method of diagnosing a disease or condition in a subject, the method comprising contacting, *in vitro*, a sample from the subject with an antibody, or antigen binding fragment, according to any one of claims 1 to 5 and detecting the formation of a complex of antibody, or antigen binding fragment, and TIM-3.

19. A method of selecting or stratifying a subject for treatment with a modulator of TIM-3 signalling, the method comprising contacting, *in vitro*, a sample from the subject with an antibody, or antigen binding fragment, according to any one of claims 1 to 5 and detecting the formation of a complex of antibody, or antigen binding fragment, and TIM-3.

20. Use of an antibody, or antigen binding fragment, according to any one of claims 1 to 5 for the detection of TIM-3 *in vitro*.

21. Use of an antibody, or antigen binding fragment, according to any one of claims 1 to 5 as an *in vitro* diagnostic agent.

22. A method for expanding a population of T cells, wherein T cells are contacted *in vitro* or *ex vivo* with an antibody or antigen binding fragment according to any one of claims 1 to 5.

23. A chimeric antigen receptor (CAR) comprising an antigen binding fragment according to any one of claims 1 to 5.